BMS-262084 is a potent, selective and irreversible inhibitor of factor XIa, with an IC 50 of 2.8 nM against human factor XIa. BMS-262084 also inhibits human tryptase (IC 50 =5 nM). BMS-262084 exhibits antithrombotic effects.
性状
Solid
IC50 & Target[1][2]
IC50: 2.8 nM (factor XIa), 5 nM (tryptase)
体外研究(In Vitro)
BMS-262084 shows more than 70-fold selectivity for human factor XIa (IC50=2.8 nM) over tryptase, trypsin, urokinase, plasma kallikrein, plasmin, yhrombin (factor IIa) and Factor IXa (IC50=0.005, 0.05, 0.542, 0.55, 1.7,10.5, and 17.4 μM, respectively).BMS-262084 (1-100 μM) doubles the activated thromboplastin time in human and rat plasma at 0.14 and 2.2 μM, respectively. has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究(In Vivo)
BMS-262084 (2-12 mg/kg + 2-12 mg/kg/h; i.v.) reduces carotid artery thrombus weight and improves both vessel patency and integrated flow in rats. has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model:
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years;4°C 2 years
参考文献
[1]. Schumacher WA, et, al. Antithrombotic and hemostatic effects of a small molecule factor XIa inhibitor in rats. Eur J Pharmacol. 2007 Sep 10;570(1-3):167-74.[2]. Qian X, et, al. A stereoselective synthesis of BMS-262084, an azetidinone-based tryptase inhibitor. J Org Chem. 2002 May 31;67(11):3595-600.
溶解度数据
In Vitro: DMSO : 50 mg/mL (117.51 mM; ultrasonic and warming and heat to 60°C)配制储备液